Developments Bellerophon gets FDA orphan drug designation for IPF therapy Bellerophon Therapeutics (NASDAQ:BLPH) received FDA orphan drug designation for the treatment of idiopathic pulmonary fibrosis (IPF) with nitric oxide. IPF is a progressive and fatal lung disease caused by the... September 16, 2019